SONICS - Effectiveness of Specialist Oncology Nursing
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00182234|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : June 18, 2009
|Condition or disease||Intervention/treatment||Phase|
|Continuity of Care Quality of Life||Behavioral: Community Interlink Program||Phase 3|
Main Research Question: Does community-based specialist oncology nursing case management improve continuity of cancer care and lead to fewer unmet cancer patient needs?
Why this research is important: This research proposal addresses the issue of gaps in continuity of supportive care for cancer patients during the early phases of the disease trajectory that result in unmet needs and unnecessary morbidity, prior to entry into a formalized cancer care system (e.g., a regional cancer centre or hospital with a cancer treatment program). This initial diagnostic period of cancer is associated with significant stress, anxiety and uncertainty that can impact upon overall quality of life for all types of cancer. These problems are further exacerbated by waiting times of up to 16 weeks between diagnosis and attendance in a formalized cancer treatment system. During this time patients will face a fragmented supportive care service system resulting in a substantial number of patients reporting unmet needs and distress. These care gaps have significant implications considering that 38% of women and 41% of men will develop cancer during their lifetime and that cancer incidence continues to rise with an estimated 139,000 new cases in Canada (over 54,000 of these in Ontario) in 2003. There has been growing interest in nursing models to address these gaps in supportive cancer care but at this time there is not sufficient high quality evidence upon which to base policy decisions to support the widespread introduction of this type of model. The results of this study will be very important for policy development for community cancer care in Ontario and in other provinces in Canada.
What is being studied: We will study the impact of a specialized nursing intervention (Interlink) on patient outcomes early in the disease trajectory. Impact will be assessed directly using validated measures in a randomized controlled trial design. These measures will include: continuity of care, unmet needs, psychological distress, uncertainty in illness, and quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||183 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)|
|Study Start Date :||December 2005|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
Behavioral: Community Interlink Program
- Difference in unmet supportive care needs between intervention and control group [ Time Frame: 2 to 3 weeks after baseline; 8 to 10 weeks after baseline ]
- Difference in continuity of care between intervention and control group [ Time Frame: 2 to 3 weeks after baseline; 8 to 10 weeks after baseline ]
- Difference in quality of life between intervention and control group [ Time Frame: 2 to 3 weeks after baseline; 8 to 10 weeks after baseline ]
- Difference in uncertainty in illness between intervention and control group [ Time Frame: 2 to 3 weeks after baseline; 8 to 10 weeks after baseline ]
- Difference in use of resources between intervention and control group [ Time Frame: 2 to 3 weeks after baseline; 8 to 10 weeks after baseline ]
- Acute stress following surgery [ Time Frame: 8 to 10 weeks after baseline ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00182234
|Principal Investigator:||Jonathan Sussman, MD, CCFP, FRCP (c), MSc||Supportive Cancer Care Research Unit|